UK markets closed

NuCana plc (NCNA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.6000+0.0400 (+2.56%)
At close: 03:59PM EST
1.6100 +0.01 (+0.62%)
After hours: 07:37PM EST

NuCana plc

3 Lochside Way
Edinburgh EH12 9DT
United Kingdom
44 13 1357 1111

Full-time employees31

Key executives

NameTitlePayExercisedYear born
Mr. Hugh Stephen GriffithFounder, CEO & Exec. Director1.12MN/A1968
Mr. Donald MunozChief Financial OfficerN/AN/A1969
Mr. David HarrisonHead of Translational MedicineN/AN/A1960
Dr. Jeffrey D. Bloss F.A.C.O.G., M.D.Chief Medical OfficerN/AN/A1957
Prof. Christopher B. Wood FRCS, M.D., Ph.D.Chief Medical OfficerN/AN/A1946
Ms. Theresa BruceSr. VP of Clinical OperationsN/AN/AN/A
Ms. Elisabeth OelmannSr. VP of Medical & Clinical Devel.N/AN/AN/A
Martin QuinnCompany Sec.N/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

Corporate governance

NuCana plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.